The expanding use of CAR-T cell therapy is creating new opportunities for Ireland’s pharmaceutical sector as advanced treatments move further into clinical practice. Legend Biotech’s latest results provide a timely example, with CARVYKTI net trade sales increasing 50% year-on-year to approximately $657 million and the therapy launching in Ireland during the second quarter. Legend Biotech’s second-quarter results point to growing commercial momentum while highlighting the wider infrastructure needed to support increasingly sophisticated cell therapies.

CAR-T therapies are different from conventional medicines because their development and delivery involve highly specialised processes. Patient cells are collected, transported to specialised manufacturing facilities, genetically engineered and then returned for administration. This creates a closely coordinated chain spanning manufacturing, quality, logistics, healthcare providers and specialist treatment centres. Irish industry reporting on expanded CAR-T access highlights the complexity of these processes and the importance of connecting manufacturing capability with clinical delivery.

For Ireland, the growing availability of these therapies provides an opportunity to build on an established pharmaceutical ecosystem while developing greater expertise in advanced therapeutic medicinal products. The Advanced Therapeutics Ireland platform brings together companies, academic institutions, researchers and government agencies working across cell therapies, gene therapies and other advanced modalities. Its development reflects an increasingly collaborative approach to supporting a sector that requires expertise across science, manufacturing, regulation and commercialisation.

Research capability is also expanding. Trinity College Dublin’s Rinn Advanced Therapies centre was established in 2026 to advance research and translation in personalised cellular immunotherapies, with expertise spanning cell bioprocessing, personalised therapeutics and related technologies. Such initiatives can help strengthen the connection between academic research and the industrial capabilities required to bring advanced therapies through development and into wider use.

Manufacturing will remain an important part of that opportunity. CAR-T production has historically involved complex and highly manual processes, creating challenges around consistency, scalability, cost and accessibility. Recent research into CAR-T manufacturing highlights the industry's movement towards more structured and standardised manufacturing platforms as developers seek to make these therapies more scalable.

Legend’s pipeline also demonstrates why this capability will need to keep evolving. Alongside CARVYKTI, the company reported first-in-human proof-of-concept data for its investigational in-vivo CAR-T candidate LB2501. In-vivo approaches aim to generate therapeutic cells within the patient rather than relying entirely on conventional ex-vivo manufacturing, illustrating how rapidly the field continues to develop. Legend Biotech’s results provide a snapshot of that broader transition.

For Ireland’s pharmaceutical industry, this creates several opportunities. Manufacturers can continue developing capabilities suited to advanced therapies, while engineering, automation and digital specialists can support increasingly sophisticated production environments. Logistics providers and healthcare organisations will also play an important role in maintaining the controlled, coordinated processes required from cell collection through to treatment.

The expansion of CAR-T therefore represents more than another product launch. It demonstrates how pharmaceutical innovation is increasingly connecting manufacturing, research, healthcare delivery and specialised supply chains. Ireland’s existing life-sciences strengths provide a strong foundation for participating in that evolution, while emerging research and advanced-therapy initiatives can help develop the capabilities needed for the next generation of treatments.

The opportunity is to build on this momentum. As advanced therapies become more widely available, continued collaboration between pharmaceutical companies, researchers, manufacturers, healthcare providers and policymakers can help ensure Ireland remains well positioned to support their development and delivery. CAR-T’s progress shows that the future of pharmaceutical innovation will depend not only on discovering new therapies, but also on building the systems and capabilities that allow them to reach patients effectively.